Prodeon Medical

Executive Summary

Prodeon Medical is a private medical device company headquartered in Salt Lake City, Utah, founded in 2010. Initially focused on ENT devices, the company has pivoted to urology with its lead investigational product, the Urocross Expander System for the Prostatic Urethral Reshaping (PURE) procedure. This minimally invasive implant aims to treat Benign Prostatic Hyperplasia (BPH) by reshaping the prostatic urethra, offering potential advantages over current therapies such as TURP or medication, including quicker recovery and preservation of sexual function. With BPH impacting a large and growing patient population, the market opportunity is substantial. However, the device remains in the investigational stage, and the company has not publicly disclosed its clinical trial status, funding, or valuation, indicating an early- to mid-stage development profile. Success will depend on demonstrating safety and efficacy in clinical studies and navigating the FDA regulatory pathway.

Upcoming Catalysts (preview)

• Q4 2026Release of pivotal clinical trial data for Urocross Expander System60% success
• H1 2027FDA 510(k) clearance or Investigational Device Exemption (IDE) approval50% success
• TBDStrategic partnership or licensing agreement with a major urology device company30% success